Gynecologic Cancer | Norton Healthcare

Indication: Gynecologic Cancer

A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer


Sub-indication: Epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Line of Therapy: Front-line neoadjuvant and post surgical therapy.

Drug Study

Principal Investigator: Mary Gordinier, M.D.
Norton Cancer Institute

Sponsor: NRG Oncology

Learn more at

Email for more information:

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.